Alkermes (NASDAQ: ALKS) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Valuation and Earnings

This table compares Alkermes and ANI Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alkermes $745.69 million 10.85 -$208.44 million ($1.11) -47.40
ANI Pharmaceuticals $128.62 million 6.00 $3.93 million $0.64 103.55

ANI Pharmaceuticals has lower revenue, but higher earnings than Alkermes. Alkermes is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alkermes and ANI Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alkermes -16.69% -12.18% -8.36%
ANI Pharmaceuticals 4.45% 22.40% 11.14%

Risk and Volatility

Alkermes has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 2.91, indicating that its stock price is 191% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Alkermes and ANI Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes 0 5 5 0 2.50
ANI Pharmaceuticals 0 1 2 0 2.67

Alkermes presently has a consensus price target of $64.50, suggesting a potential upside of 22.58%. ANI Pharmaceuticals has a consensus price target of $70.33, suggesting a potential upside of 6.13%. Given Alkermes’ higher possible upside, research analysts plainly believe Alkermes is more favorable than ANI Pharmaceuticals.

Institutional and Insider Ownership

99.7% of Alkermes shares are owned by institutional investors. Comparatively, 55.1% of ANI Pharmaceuticals shares are owned by institutional investors. 5.3% of Alkermes shares are owned by insiders. Comparatively, 31.8% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

ANI Pharmaceuticals beats Alkermes on 8 of the 13 factors compared between the two stocks.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company’s products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company’s product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.